{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:37:52Z","timestamp":1767825472547,"version":"3.49.0"},"reference-count":29,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2014,5,8]]},"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>5-Amino salicylate (5-ASA) medications may rarely be associated with a significant decline in renal function and interstitial nephritis. British Society of Gastroenterology guidelines advise regular renal function monitoring for patients taking these drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess whether gastroenterologists in Kent were following best practice guidelines regarding the monitoring of their patients on 5-ASA therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using longitudinal community and regional pathology databases for the Kent population, our renal unit regularly screens a total population of 300\u2005000 for evidence of renal disease. The data extracted are analysed using an automated computerised system to identify patients requiring intervention for kidney disease. All patients taking 5-ASA medication were identified from a population of 300\u2005000. The pathology database was studied to identify the patients on 5-ASA treatment and whether they had had renal function tests.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>800 adult patients were identified taking 5-ASA therapy. 612 patients received 5-ASAs for 3\u2005months or more, and these were included in the final analysis. 293 patients had no renal function checks while on treatment. 79 patients had renal function tests less than once every 4\u2005years and 36 patients once every 2\u20134 years. 204 patients had renal function measurements in 50% or more of years of treatment, of whom 116 were checked every year. Some patients were started on treatment with abnormal results at baseline and some with identified kidney disease continued on their 5-ASAs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The majority of patients receiving 5-ASA compounds do not have regular renal function monitoring. Clinicians are failing to follow best practice guidelines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2014-100452","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T22:09:18Z","timestamp":1401919758000},"page":"27-31","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment"],"prefix":"10.1136","volume":"6","author":[{"given":"N","family":"Siddique","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Kent & Canterbury Hospital, Kent, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Farmer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Kent & Canterbury Hospital, Kent, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A F","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Kent & Canterbury Hospital, Kent, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"2025090707584155000_6.1.27.1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad-Khan","year":"1977","journal-title":"Lancet"},{"key":"2025090707584155000_6.1.27.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02462.x"},{"key":"2025090707584155000_6.1.27.3","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20099"},{"key":"2025090707584155000_6.1.27.4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00467-004-1411-6","article-title":"Interstitial nephritis from mesalazine: case report and literature review","volume":"19","author":"Arend","year":"2004","journal-title":"Paediatric Nephrol"},{"key":"2025090707584155000_6.1.27.5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027349"},{"key":"2025090707584155000_6.1.27.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.016"},{"key":"2025090707584155000_6.1.27.7","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.MIB.0000185402.65288.19","article-title":"5-Aminosalicylates and effects on renal function in patients with Crohn's disease","volume":"11","author":"de Jong","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"2025090707584155000_6.1.27.8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1155\/2009\/501345","article-title":"Renal effects of long-term treatment with 5-aminosalicylic acid","volume":"23","author":"Patel","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"2025090707584155000_6.1.27.9","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.6.761"},{"key":"2025090707584155000_6.1.27.10","first-page":"51","article-title":"Early renal failure after mesalazine (case report)","volume":"144","author":"Musil","year":"2000","journal-title":"Acta Univ Palace Olumuc, Fac Med"},{"key":"2025090707584155000_6.1.27.11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/bmj.317.7161.795","article-title":"Late onset interstitial nephritis associated with mesalazine treatment","volume":"317","author":"Popoola","year":"1998","journal-title":"Br Med J"},{"key":"2025090707584155000_6.1.27.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090707584155000_6.1.27.13","unstructured":"http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con132066.pdf 2011;12."},{"key":"2025090707584155000_6.1.27.14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.224154"},{"key":"2025090707584155000_6.1.27.15","first-page":"262","article-title":"Akute interstitielle Nephritis durch 5-Aminosalicylsaeure?","volume":"30","author":"Ruf-ballauf","year":"1989","journal-title":"Internist"},{"key":"2025090707584155000_6.1.27.16","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.4.563"},{"key":"2025090707584155000_6.1.27.17","first-page":"1031","article-title":"Acute interstitial nephritis due to 5-aminosalicylic acid","volume":"143","author":"Mehta","year":"1990","journal-title":"Can Med Assoc J"},{"key":"2025090707584155000_6.1.27.18","first-page":"236","article-title":"Nephritis durch 5-Aminosalicylsaeure","volume":"114","author":"von Muehlendahl","year":"1989","journal-title":"Dtsche Med Wochenschr"},{"key":"2025090707584155000_6.1.27.19","first-page":"1090","article-title":"Chronische interstitielle Nephritis nach Behandlung mit 5-Aminosalicylsaeure","volume":"114","author":"Henning","year":"1989","journal-title":"Dtsche Med Wochenschr"},{"key":"2025090707584155000_6.1.27.20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.10.1493"},{"key":"2025090707584155000_6.1.27.21","first-page":"2557","article-title":"Tubulo- interstitiele nefritis door mesalazine (S-ASA)-preparaten","volume":"138","author":"Smilde","year":"1994","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2025090707584155000_6.1.27.22","unstructured":"Mid-2010 Population Estimates for Primary Care Organisations in England. ONS 2011."},{"key":"2025090707584155000_6.1.27.23","doi-asserted-by":"publisher","DOI":"10.1038\/ng.379"},{"key":"2025090707584155000_6.1.27.24","doi-asserted-by":"publisher","DOI":"10.4103\/2231-0770.94804"},{"key":"2025090707584155000_6.1.27.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6634.1442"},{"key":"2025090707584155000_6.1.27.26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"2025090707584155000_6.1.27.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.08.013"},{"key":"2025090707584155000_6.1.27.28","doi-asserted-by":"crossref","unstructured":"Standards for the healthcare of people who have inflammatory bowel disease (IBD): IBD Standards 2013 Update (number 11). http:\/\/www.bsg.org.uk\/docs\/clinical\/ibd_standards_13.pdf .","DOI":"10.12968\/gasn.2013.11.10.28"},{"key":"2025090707584155000_6.1.27.29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304907.049"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2014-100452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:58:48Z","timestamp":1757257128000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2014-100452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,5]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1136\/flgastro-2014-100452"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2014-100452","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,4]]}}}